Zymeworks (NASDAQ: ZYME) net income
Zymeworks reported a net loss of $81.1m for fiscal 2025; in fiscal 2024 it reported a net loss of $122.7m. Earnings per share were −$1.08.
Zymeworks's best year of the last 5 was fiscal 2022. It reported a loss in 4 of those 5 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$81.1m | — | −76.6% | −$1.08 |
| 2024 | −$122.7m | — | −160.8% | −$1.62 |
| 2023 | −$118.7m | −195.4% | −156.1% | −$1.72 |
| 2022 | $124.3m | — | 30.1% | $1.91 |
| 2021 | −$211.8m | — | −794.0% | −$4.11 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Zymeworks net income compared with its sector
By net income for its latest fiscal year, Zymeworks ranks 317th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Zymeworks, −76.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 315th | Bioage Labs | −$80.6m | −896.1% |
| 316th | Arvinas | −$80.8m | −30.8% |
| 317th | Zymeworks | −$81.1m | −76.6% |
| 318th | Personalis | −$81.3m | −116.7% |
| 319th | Enanta Pharmaceuticals | −$81.9m | −125.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Zymeworks
- How much did Zymeworks earn in fiscal 2025?
- Zymeworks reported a net loss of $81.1m for fiscal 2025. In fiscal 2024 it reported a net loss of $122.7m.
- What are the earnings per share of Zymeworks?
- They were −$1.08 in fiscal 2025, compared with −$1.62 in fiscal 2024.
- What was the most profitable year for Zymeworks?
- Of its last 5 fiscal years, fiscal 2022, with $124.3m.
- Where does Zymeworks rank in its sector by net income?
- It ranks 317th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Zymeworks come from?
- From the annual report (Form 10-K) that Zymeworks files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Zymeworks files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Zymeworks: the Zymeworks page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.